as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹55.93
Change
+0.17 (0.3%)
Open
₹56.79
Prev. Close
₹55.76
Day High
₹57.28
Day Low
₹55.58
Volume Analysis
Traded
1,803,626
Delivered
945,485
Delivery %
52.42%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (28.9%)
- •Strong operating margin (62.0%)
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹58.64 | ₹57.96 | ₹56.94 | ₹56.26 | ₹55.24 | ₹54.56 | ₹53.54 |
| Fibonacci | ₹57.96 | ₹57.31 | ₹56.91 | ₹56.26 | ₹55.61 | ₹55.21 | ₹54.56 |
| Camarilla | ₹56.4 | ₹56.24 | ₹56.09 | ₹56.26 | ₹55.77 | ₹55.62 | ₹55.46 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+1.08%
1 Month
+26.31%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹4.8
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
28.88%
Net margin 45.33% × asset turnover 0.49x × equity multiplier 1.3x
Company Overview
Sector
Healthcare
Market Cap
₹2,465 Cr
P/E (TTM)
72.6
ROE
28.9%
Book Value
₹2.05
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Shukra Pharmaceuticals L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 58/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (28.9%); strong operating margin (62.0%).
TopFund Score — Fundamentals Quality
58/100 — AverageData confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- −Stock is trading at 27.3 times its book value
- −Debtor days have increased from 123 to 148 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Trading window closed from October 1, 2026 until 48 hours after Q2 FY27 results.
Corrigendum to August 22, 2026 postal ballot for name change to Shukra Medtech Limited and MOA alteration.
Shukra Pharmaceuticals AGM on 28 Sep 2026; 1% final dividend, financial statements adoption, director reappointment.
Shukra Pharmaceuticals schedules 33rd AGM on 28 Sep 2026; proposes 1% final dividend and director regularisation.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 11 | 13 | 5 | 6 | 39 | 6 | 24 |
| Expenses + | 7 | 6 | 4 | 6 | 12 | 6 | 4 |
| Operating Profit | 4 | 7 | 1 | 0 | 27 | 1 | 19 |
| OPM % | 37.0% | 55.0% | 24.0% | -7.0% | 69.0% | 11.0% | 81.0% |
| Other Income + | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 8 | 1 | 0 | 27 | 0 | 18 |
| Tax % | 23.0% | 29.0% | 26.0% | -1,090.0% | 24.0% | 553.0% | 29.0% |
| Net Profit + | 3 | 5 | 1 | 2 | 20 | -2 | 13 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales + | 33 | 57 | 75 |
| Expenses + | 20 | 28 | 28 |
| Operating Profit | 13 | 29 | 47 |
| OPM % | 39.0% | 51.0% | 62.0% |
| Other Income + | 4 | 5 | 4 |
| Interest | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 4 |
| Profit before tax | 13 | 29 | 46 |
| Tax % | 28.0% | 23.0% | — |
| Net Profit + | 10 | 22 | 34 |
| EPS in Rs | 0 | 1 | 1 |
| Dividend Payout % | 0.0% | 2.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Reserves | 19 | 46 |
| Borrowings + | 4 | 5 |
| Other Liabilities + | 20 | 23 |
| Total Liabilities | 87 | 117 |
| Fixed Assets + | 19 | 22 |
| CWIP | 2 | 12 |
| Investments | 0 | 0 |
| Other Assets + | 65 | 84 |
| Total Assets | 87 | 117 |
| Equity Capital | 44 | 44 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity + | 8 | 4 |
| Cash from Investing Activity + | -1 | -14 |
| Cash from Financing Activity + | -5 | 4 |
| Net Cash Flow | 2 | -6 |
| CFO/OP | 92 | 19 |
| Free Cash Flow | 5 | -12 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.93% | 48.74% |
| Promoters | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 51.16% |
| DII | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Shukra Pharmaceuticals L (this stock) | 2,465 | 72.6 | 27.27 | 28.9% |
| Sakar Healthcare Limited | 2,527 | 70.0 | 7.78 | 9.99% |
| Fischer Medical Venture L | 2,401 | 98.1 | 5.85 | 8.91% |
| Beta Drugs Limited | 2,400 | 52.6 | 8.98 | 18.8% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
| Fredun Pharmaceuticals L | 2,305 | 52.6 | 8.2 | 15.6% |
| Panacea Biotec Ltd | 2,282 | — | 2.74 | -2.42% |
Which Mutual Funds Hold Shukra Pharmaceuticals L?
Frequently Asked Questions about Shukra Pharmaceuticals L
Shukra Pharmaceuticals L (SHUKRAPHAR) closed at ₹55.93 on NSE on 25 September 2026, up 0.17 (0.3%) from the previous close.
Shukra Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol SHUKRAPHAR.
Shukra Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 72.6.
Shukra Pharmaceuticals L has a dividend yield of 0.02%.
Shukra Pharmaceuticals L's 52-week high is ₹65.3 and its 52-week low is ₹26.3.
Shukra Pharmaceuticals L has a market capitalisation of ₹2,465 crore.
Shukra Pharmaceuticals L has a TopFund Quality Score of 58/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Shukra Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.